Skip to main content

Specialty Pharmacy

  • Impax, Banner to develop two softgel capsule products

    HAYWARD, Calif., and HIGH POINT, N.C. — Impax Labs will collaborate with a specialty pharmaceutical company dedicated to the research, development and manufacturing of unique gelatin-based dosage forms.

    Impax said it has entered a deal with Banner Pharmacaps in respect to the supply and commercialization of two softgel capsule products.

    The products and terms of the agreement were not disclosed.

  • Pfizer, Zacharon enter collaboration

    SAN DIEGO — Pfizer is partnering with San Diego biotech company Zacharon Pharmaceuticals to develop treatments for rare genetic disorders Zacharon said Thursday.

    Under the collaboration, which could garner Zacharon up to $210 million, the companies will discover and develop pharmaceutical drugs for treating lysosomal storage disorders, a class of illnesses that includes Fabry disease, Gaucher disease, Pompe disease and Tay-Sachs disease.

  • Shionogi launches Cuvposa, partners with Diplomat Specialty Pharmacy

    FLORHAM PARK, N.J. — A treatment made by Shionogi for chronic, severe drooling in children and teenagers with neurological conditions has become available, the drug maker said Thursday.

  • AstraZeneca's vandetanib receives approval from FDA

    SILVER SPRING, Md. — The Food and Drug Administration has approved a drug made by AstraZeneca for treating a rare form of thyroid cancer, the agency said.

    The FDA announced the approval of the daily pill vandetanib for late-stage medullary thyroid cancer in patients whose disease is growing and causing symptoms but who are ineligible for surgery.

    Medullary thyroid cancer involves specific cells found in the thyroid gland and can occur spontaneously or be part of a genetic disease. There currently are no FDA-approved treatments for this cancer.

  • Walgreens VP to present during Pinsonault Associates Managed Markets Summit

    DEERFIELD, Ill. — Walgreens VP clinical affairs David Lorber will present during the Pinsonault Associates Managed Markets Summit on April 12 in Miami, Fla., the retailer announced Thursday.

    The session, titled "Employer Issues in Specialty Pharmacy," will examine concerns for payers, including cost management and containment, benefit and coverage decisions, formulary and medical policy, pipeline management, provider network, member satisfaction and disruption, and compliance.

  • BioScrip receives URAC accreditation

    ELMSFORD, N.Y. — Washington-based healthcare accrediting organization URAC has awarded specialty pharmacy and mail-service pharmacy accreditation to BioScrip, the specialty pharmacy provider said Wednesday.

  • Viramune XR approved by the FDA

    RIDGEFIELD, Conn. — The Food and Drug Administration has approved Boehringer Ingelheim Pharmaceuticals' single-pill antiretroviral for HIV-1 patients, BI said Tuesday.

    The FDA approved Viramune XR (nevirapine), a single-pill, once-daily, extended-release formulation of nevirapine for use in combination with other antiretroviral drugs.

  • BioPlus appoints chief strategic officer

    ALTAMONTE SPRINGS, Fla. — A former MedfusionRx VP has joined BioPlus as its new chief strategic officer.

    In his new role, Russell Gay will provide key leadership for all of the business development at BioPlus, including the strengthening and growth of relationships with payers, physicians, the pharmaceutical industry and various industry partners, BioPlus said.

X
This ad will auto-close in 10 seconds